MoonRISe-1

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

• Studientyp: randomisierte Studie
• Tumorart: Urogenitale Tumoren
• Entität: Blasenkarzinom
• Standort:
  • Klinikum Stuttgart
  • E-Mail: scc-studienzentrale@klinikum-stuttgart.de
  • Tel.: 0711 278-30410
  • Website
• Rekrutierungsstatus: rekrutierend
• Alter: 18+
• Studienphase: Phase3
• Weitere Informationen